Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Eidos Therapeutics, Inc.EIDX · Entity 143355 | CFO and Secretary | December 09, 2019 | December 11, 2019 |
| Monte Rosa Therapeutics, Inc.GLUE · Entity 4828 | Director | June 11, 2026 | June 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Eidos Therapeutics, Inc.
Report date December 09, 2019 · Filed December 11, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 36,470 |
Ending reported balance
After 2019-12-09 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2019-12-09 · Exercise / conversion · Acquired 10,000 · Balance 46,470 Row 2 · 2019-12-09 · Sale · Disposed 9,099 · Balance 37,371 F1: Represents the weighted average sale price of the shares sold from $59.00 to $59.99 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions as reported in footnotes 1 and 2. Row 3 · 2019-12-09 · Sale · Disposed 901 · Balance 36,470 F2: Represents the weighted average sale price of the shares sold from $60.01 to $60.115 per share. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.59 · Expires 2027-12-21 | Direct | 152,191 |
Reported balance
After 2019-12-09 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-12-09 · Exercise / conversion · Disposed 10,000 · Balance 152,191 F3: The shares subject to this option vest and become exercisable in 48 equal monthly installments after December 1, 2017, subject to the Reporting Person's continuous service to the Issuer through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the weighted average sale price of the shares sold from $59.00 to $59.99 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions as reported in footnotes 1 and 2.
F2: Represents the weighted average sale price of the shares sold from $60.01 to $60.115 per share.
F3: The shares subject to this option vest and become exercisable in 48 equal monthly installments after December 1, 2017, subject to the Reporting Person's continuous service to the Issuer through each such vesting date.
Monte Rosa Therapeutics, Inc.
Report date June 11, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.10 · Expires 2036-06-11 | Direct | 25,800 |
Reported balance
After 2026-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 25,800 · Balance 25,800 F1: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 11, 2027 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service at such time. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 11, 2027 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service at such time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 11, 2026 Filed Jun 12, 2026 16:05 UTC | Monte Rosa Therapeutics, Inc. GLUE · Entity 4828 | GrantStock Option (Right to Buy) · Derivative | 25,800 | $0.00 Strike: $17.10 | $0.00 |
DisclosureSEC source: 0001193125-26-269368 · ownership.xml · derivative · entry 1 Siu Christine · CIK 0001743029 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,800 Underlying: Common Stock · 25,800 shares Expires 2036-06-11 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 11, 2027 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service at such time. Read SEC document |
| June 13, 2025 Filed Jun 16, 2025 16:05 UTC | Monte Rosa Therapeutics, Inc. GLUE · Entity 4828 | GrantStock Option (Right to Buy) · Derivative | 30,700 | $0.00 Strike: $4.91 | $0.00 |
DisclosureSEC source: 0000950170-25-086701 · ownership.xml · derivative · entry 1 Siu Christine · CIK 0001743029 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,700 Underlying: Common Stock · 30,700 shares Expires 2035-06-13 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 13, 2026 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service at such time. Read SEC document |
| June 12, 2024 Filed Jun 13, 2024 16:30 UTC | Monte Rosa Therapeutics, Inc. GLUE · Entity 4828 | GrantStock Option (Right to Buy) · Derivative | 22,100 | $0.00 Strike: $4.16 | $0.00 |
DisclosureSEC source: 0000950170-24-073073 · ownership.xml · derivative · entry 1 Siu Christine · CIK 0001743029 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,100 Underlying: Common Stock · 22,100 shares Expires 2034-06-12 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 12, 2025 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service at such time. Read SEC document |
| June 14, 2023 Filed Jun 15, 2023 16:28 UTC | Monte Rosa Therapeutics, Inc. GLUE · Entity 4828 | GrantStock Option (Right to Buy) · Derivative | 20,500 | $0.00 Strike: $6.59 | $0.00 |
DisclosureSEC source: 0001209191-23-037354 · doc4.xml · derivative · entry 1 Siu Christine · CIK 0001743029 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,500 Underlying: Common Stock · 20,500 shares Expires 2033-06-13 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 14, 2024 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service at such time. Read SEC document |
| June 15, 2022 Filed Jun 16, 2022 16:32 UTC | Monte Rosa Therapeutics, Inc. GLUE · Entity 4828 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $7.66 | $0.00 |
DisclosureSEC source: 0001209191-22-037432 · doc4.xml · derivative · entry 1 Siu Christine · CIK 0001743029 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2032-06-14 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 15, 2023 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service at such time. Read SEC document |
| June 23, 2021 Filed Jun 25, 2021 17:01 UTC | Monte Rosa Therapeutics, Inc. GLUE · Entity 4828 | GrantStock Option (Right to Buy) · Derivative | 47,132 | $0.00 Strike: $19.00 | $0.00 |
DisclosureSEC source: 0000899243-21-025977 · doc4.xml · derivative · entry 2 Siu Christine · CIK 0001743029 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,132 Underlying: Common Stock · 47,132 shares Expires 2031-06-22 F4 · derivative.exercise_date: This option shall vest in 36 substantially equal monthly installments, with the first installment vesting on June 28, 2021. Read SEC document |
| April 12, 2021 Filed Jun 25, 2021 17:01 UTC | Monte Rosa Therapeutics, Inc. GLUE · Entity 4828 | GrantStock Option (Right to Buy) · Derivative | 7,081 | $0.00 Strike: $6.14 | $0.00 |
DisclosureSEC source: 0000899243-21-025977 · doc4.xml · derivative · entry 1 Siu Christine · CIK 0001743029 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,081 Underlying: Common Stock · 7,081 shares Expires 2031-04-12 F1 · derivative.exercise_price: On June 17, 2021, the Issuer completed a one-for-3.5305 reverse stock split of the Issuer's Common Stock (the "Reverse Split"). This amount has been adjusted to give effect to the Reverse Split. F2 · kind: This transaction occurred prior to the Issuer's initial public offering, and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The securities covered by such transaction were previously included on the Reporting Person's Form 3. F1 · shares: On June 17, 2021, the Issuer completed a one-for-3.5305 reverse stock split of the Issuer's Common Stock (the "Reverse Split"). This amount has been adjusted to give effect to the Reverse Split. F3 · derivative.exercise_date: 25% of this option shall vest and become exercisable on April 9, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter. F1 · derivative.underlying_shares: On June 17, 2021, the Issuer completed a one-for-3.5305 reverse stock split of the Issuer's Common Stock (the "Reverse Split"). This amount has been adjusted to give effect to the Reverse Split. F1 · balance_after: On June 17, 2021, the Issuer completed a one-for-3.5305 reverse stock split of the Issuer's Common Stock (the "Reverse Split"). This amount has been adjusted to give effect to the Reverse Split. Read SEC document |
| December 09, 2019 Filed Dec 11, 2019 16:44 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $0.59 | $0.00 |
DisclosureSEC source: 0000899243-19-028932 · doc4.xml · derivative · entry 4 Siu Christine · CIK 0001743029 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,191 Underlying: Common Stock · 10,000 shares Expires 2027-12-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to this option vest and become exercisable in 48 equal monthly installments after December 1, 2017, subject to the Reporting Person's continuous service to the Issuer through each such vesting date. Read SEC document |
| December 09, 2019 Filed Dec 11, 2019 16:44 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | SaleCommon Stock | 901 | $60.05 | $54,101.09 |
DisclosureSEC source: 0000899243-19-028932 · doc4.xml · nonDerivative · entry 3 Siu Christine · CIK 0001743029 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,470 F2 · price: Represents the weighted average sale price of the shares sold from $60.01 to $60.115 per share. Read SEC document |
| December 09, 2019 Filed Dec 11, 2019 16:44 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | SaleCommon Stock | 9,099 | $59.62 | $542,468.73 |
DisclosureSEC source: 0000899243-19-028932 · doc4.xml · nonDerivative · entry 2 Siu Christine · CIK 0001743029 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,371 F1 · price: Represents the weighted average sale price of the shares sold from $59.00 to $59.99 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions as reported in footnotes 1 and 2. Read SEC document |
| December 09, 2019 Filed Dec 11, 2019 16:44 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | Exercise / conversionCommon Stock | 10,000 | $0.59 | $5,900.00 |
DisclosureSEC source: 0000899243-19-028932 · doc4.xml · nonDerivative · entry 1 Siu Christine · CIK 0001743029 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,470 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 04, 2019 Filed Dec 5, 2019 17:49 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $0.59 | $0.00 |
DisclosureSEC source: 0000899243-19-028602 · doc4.xml · derivative · entry 9 Siu Christine · CIK 0001743029 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,191 Underlying: Common Stock · 10,000 shares Expires 2027-12-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The shares subject to this option vest and become exercisable in 48 equal monthly installments after December 1, 2017, subject to the Reporting Person's continuous service to the Issuer through each such vesting date. Read SEC document |
| December 04, 2019 Filed Dec 5, 2019 17:49 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | SaleCommon Stock | 1,200 | $59.39 | $71,271.84 |
DisclosureSEC source: 0000899243-19-028602 · doc4.xml · nonDerivative · entry 7 Siu Christine · CIK 0001743029 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,470 F5 · price: Represents the weighted average sale price of the shares sold from $59.125 to $59.58 per share. Read SEC document |
| December 04, 2019 Filed Dec 5, 2019 17:49 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | SaleCommon Stock | 8,800 | $58.60 | $515,671.20 |
DisclosureSEC source: 0000899243-19-028602 · doc4.xml · nonDerivative · entry 6 Siu Christine · CIK 0001743029 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,670 F4 · price: Represents the weighted average sale price of the shares sold from $58.11 to $59.10 per share. Read SEC document |
| December 04, 2019 Filed Dec 5, 2019 17:49 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | Exercise / conversionCommon Stock | 10,000 | $0.59 | $5,900.00 |
DisclosureSEC source: 0000899243-19-028602 · doc4.xml · nonDerivative · entry 5 Siu Christine · CIK 0001743029 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,470 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 03, 2019 Filed Dec 5, 2019 17:49 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $0.59 | $0.00 |
DisclosureSEC source: 0000899243-19-028602 · doc4.xml · derivative · entry 8 Siu Christine · CIK 0001743029 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,191 Underlying: Common Stock · 10,000 shares Expires 2027-12-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The shares subject to this option vest and become exercisable in 48 equal monthly installments after December 1, 2017, subject to the Reporting Person's continuous service to the Issuer through each such vesting date. Read SEC document |
| December 03, 2019 Filed Dec 5, 2019 17:49 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | SaleCommon Stock | 4,000 | $59.65 | $238,582.80 |
DisclosureSEC source: 0000899243-19-028602 · doc4.xml · nonDerivative · entry 4 Siu Christine · CIK 0001743029 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,470 F3 · price: Represents the weighted average sale price of the shares sold from $59.37 to $60.35 per share. Read SEC document |
| December 03, 2019 Filed Dec 5, 2019 17:49 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | SaleCommon Stock | 5,400 | $58.95 | $318,332.16 |
DisclosureSEC source: 0000899243-19-028602 · doc4.xml · nonDerivative · entry 3 Siu Christine · CIK 0001743029 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,470 F2 · price: Represents the weighted average sale price of the shares sold from $58.37 to $59.225 per share. Read SEC document |
| December 03, 2019 Filed Dec 5, 2019 17:49 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | SaleCommon Stock | 600 | $57.82 | $34,692.72 |
DisclosureSEC source: 0000899243-19-028602 · doc4.xml · nonDerivative · entry 2 Siu Christine · CIK 0001743029 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,870 F1 · price: Represents the weighted average sale price of the shares sold from $57.275 to $58.21 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions as reported in footnotes 1 through 5. Read SEC document |
| December 03, 2019 Filed Dec 5, 2019 17:49 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | Exercise / conversionCommon Stock | 10,000 | $0.59 | $5,900.00 |
DisclosureSEC source: 0000899243-19-028602 · doc4.xml · nonDerivative · entry 1 Siu Christine · CIK 0001743029 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,470 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 22, 2019 Filed Nov 22, 2019 21:00 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | SaleCommon Stock | 601 | $55.29 | $33,232.23 |
DisclosureSEC source: 0000899243-19-028027 · doc4.xml · nonDerivative · entry 6 Siu Christine · CIK 0001743029 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,470 F3 · price: Represents the weighted average sale price of the shares sold from $55.21 to $55.40 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 22, 2019 Filed Nov 22, 2019 21:00 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | SaleCommon Stock | 9,399 | $54.71 | $514,223.99 |
DisclosureSEC source: 0000899243-19-028027 · doc4.xml · nonDerivative · entry 5 Siu Christine · CIK 0001743029 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,071 F2 · price: Represents the weighted average sale price of the shares sold from $54.21 to $55.19 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 22, 2019 Filed Nov 22, 2019 21:00 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | Exercise / conversionCommon Stock | 10,000 | $0.59 | $5,900.00 |
DisclosureSEC source: 0000899243-19-028027 · doc4.xml · nonDerivative · entry 4 Siu Christine · CIK 0001743029 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,470 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 21, 2019 Filed Nov 22, 2019 21:00 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $0.59 | $0.00 |
DisclosureSEC source: 0000899243-19-028027 · doc4.xml · derivative · entry 8 Siu Christine · CIK 0001743029 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,191 Underlying: Common Stock · 10,000 shares Expires 2027-12-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to this option vest and become exercisable in 48 equal monthly installments after December 1, 2017, subject to the Reporting Person's continuous service to the Issuer through each such vesting date. Read SEC document |
| November 21, 2019 Filed Nov 22, 2019 21:00 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | Exercise / conversionStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $0.59 | $0.00 |
DisclosureSEC source: 0000899243-19-028027 · doc4.xml · derivative · entry 7 Siu Christine · CIK 0001743029 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,191 Underlying: Common Stock · 25,000 shares Expires 2027-12-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to this option vest and become exercisable in 48 equal monthly installments after December 1, 2017, subject to the Reporting Person's continuous service to the Issuer through each such vesting date. Read SEC document |
| November 21, 2019 Filed Nov 22, 2019 21:00 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | SaleCommon Stock | 200 | $56.00 | $11,200.00 |
DisclosureSEC source: 0000899243-19-028027 · doc4.xml · nonDerivative · entry 3 Siu Christine · CIK 0001743029 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,470 Read SEC document |
| November 21, 2019 Filed Nov 22, 2019 21:00 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | SaleCommon Stock | 24,800 | $55.12 | $1,366,876.80 |
DisclosureSEC source: 0000899243-19-028027 · doc4.xml · nonDerivative · entry 2 Siu Christine · CIK 0001743029 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,670 F1 · price: Represents the weighted average sale price of the shares sold from $55.00 to $55.90 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 21, 2019 Filed Nov 22, 2019 21:00 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | Exercise / conversionCommon Stock | 25,000 | $0.59 | $14,750.00 |
DisclosureSEC source: 0000899243-19-028027 · doc4.xml · nonDerivative · entry 1 Siu Christine · CIK 0001743029 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,470 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 10, 2019 Filed Jul 12, 2019 16:05 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $0.59 | $0.00 |
DisclosureSEC source: 0000899243-19-019526 · doc4.xml · derivative · entry 3 Siu Christine · CIK 0001743029 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,191 Underlying: Common Stock · 5,000 shares Expires 2027-12-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares subject to this option vest and become exercisable in 48 equal monthly installments after December 1, 2017, subject to the Reporting Person's continuous service to the Issuer through each such vesting date. Read SEC document |
| July 10, 2019 Filed Jul 12, 2019 16:05 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | SaleCommon Stock | 5,000 | $39.37 | $196,850.00 |
DisclosureSEC source: 0000899243-19-019526 · doc4.xml · nonDerivative · entry 2 Siu Christine · CIK 0001743029 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,470 F1 · price: Represents the weighted average sale price of the shares sold from $39.24 to $39.76 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 10, 2019 Filed Jul 12, 2019 16:05 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | Exercise / conversionCommon Stock | 5,000 | $0.59 | $2,950.00 |
DisclosureSEC source: 0000899243-19-019526 · doc4.xml · nonDerivative · entry 1 Siu Christine · CIK 0001743029 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,470 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 26, 2019 Filed Jun 28, 2019 16:05 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | Exercise / conversionStock Option (right to buy) · Derivative | 17,000 | $0.00 Strike: $0.59 | $0.00 |
DisclosureSEC source: 0000899243-19-018521 · doc4.xml · derivative · entry 2 Siu Christine · CIK 0001743029 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,191 Underlying: Common Stock · 17,000 shares Expires 2027-12-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares subject to this option vest and become exercisable in 48 equal monthly installments after December 1, 2017, subject to the Reporting Person's continuous service to the Issuer through each such vesting date. Read SEC document |
| June 26, 2019 Filed Jun 28, 2019 16:05 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | Exercise / conversionCommon Stock | 17,000 | $0.59 | $10,030.00 |
DisclosureSEC source: 0000899243-19-018521 · doc4.xml · nonDerivative · entry 1 Siu Christine · CIK 0001743029 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,470 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 05, 2019 Filed Jun 7, 2019 16:52 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | SaleCommon Stock | 300 | $31.03 | $9,309.00 |
DisclosureSEC source: 0000899243-19-016042 · doc4.xml · nonDerivative · entry 4 Siu Christine · CIK 0001743029 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,470 F4 · price: Represents the weighted average sale price of the shares sold ranging from $30.81 to $31.17 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 05, 2019 Filed Jun 7, 2019 16:52 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | SaleCommon Stock | 13,421 | $30.10 | $403,972.10 |
DisclosureSEC source: 0000899243-19-016042 · doc4.xml · nonDerivative · entry 3 Siu Christine · CIK 0001743029 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,770 F3 · price: Represents the weighted average sale price of the shares sold ranging from $29.79 to $30.72 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 05, 2019 Filed Jun 7, 2019 16:52 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | SaleCommon Stock | 3,279 | $29.34 | $96,205.86 |
DisclosureSEC source: 0000899243-19-016042 · doc4.xml · nonDerivative · entry 2 Siu Christine · CIK 0001743029 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,191 F2 · price: Represents the weighted average sale price of the shares sold ranging from $28.76 to $29.75 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 31, 2019 Filed Jun 7, 2019 16:52 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | GrantCommon Stock | 1,769 | $12.01 | $21,246.57 |
DisclosureSEC source: 0000899243-19-016042 · doc4.xml · nonDerivative · entry 1 Siu Christine · CIK 0001743029 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,470 F1 · kind: Shares acquired pursuant to the Issuer's 2018 Employee Stock Purchase Plan. Read SEC document |
| April 24, 2019 Filed Apr 26, 2019 16:06 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $0.59 | $0.00 |
DisclosureSEC source: 0000899243-19-011239 · doc4.xml · derivative · entry 3 Siu Christine · CIK 0001743029 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 239,191 Underlying: Common Stock · 5,000 shares Expires 2027-12-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares subject to this option vest and become exercisable in 48 equal monthly installments after December 1, 2017, subject to the Reporting Person's continuous service to the Issuer through each such vesting date. Read SEC document |
| April 24, 2019 Filed Apr 26, 2019 16:06 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | SaleCommon Stock | 5,000 | $26.11 | $130,550.00 |
DisclosureSEC source: 0000899243-19-011239 · doc4.xml · nonDerivative · entry 2 Siu Christine · CIK 0001743029 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,701 F1 · price: Represents the weighted average sale price of the shares sold ranging from $26.00 to $26.57 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 24, 2019 Filed Apr 26, 2019 16:06 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | Exercise / conversionCommon Stock | 5,000 | $0.59 | $2,950.00 |
DisclosureSEC source: 0000899243-19-011239 · doc4.xml · nonDerivative · entry 1 Siu Christine · CIK 0001743029 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,701 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 19, 2019 Filed Mar 21, 2019 20:50 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | Exercise / conversionStock Option (right to buy) · Derivative | 34,662 | $0.00 Strike: $0.59 | $0.00 |
DisclosureSEC source: 0000899243-19-008760 · doc4.xml · derivative · entry 6 Siu Christine · CIK 0001743029 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,191 Underlying: Common Stock · 34,662 shares Expires 2027-12-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to this option vest and become exercisable in 48 equal monthly installments after December 1, 2017, subject to the Reporting Person's continuous service to the Issuer through each such vesting date. Read SEC document |
| March 19, 2019 Filed Mar 21, 2019 20:50 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | Exercise / conversionStock Option (right to buy) · Derivative | 10,871 | $0.00 Strike: $0.15 | $0.00 |
DisclosureSEC source: 0000899243-19-008760 · doc4.xml · derivative · entry 5 Siu Christine · CIK 0001743029 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,871 shares Expires 2027-03-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 19, 2019 Filed Mar 21, 2019 20:50 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | SaleCommon Stock | 11,913 | $19.66 | $234,209.58 |
DisclosureSEC source: 0000899243-19-008760 · doc4.xml · nonDerivative · entry 4 Siu Christine · CIK 0001743029 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,701 F2 · price: Represents the weighted average sale price of the shares sold ranging from $19.65 to $20.00 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 19, 2019 Filed Mar 21, 2019 20:50 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | Exercise / conversionCommon Stock | 34,662 | $0.59 | $20,450.58 |
DisclosureSEC source: 0000899243-19-008760 · doc4.xml · nonDerivative · entry 3 Siu Christine · CIK 0001743029 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,614 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 19, 2019 Filed Mar 21, 2019 20:50 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | Exercise / conversionCommon Stock | 10,871 | $0.15 | $1,630.65 |
DisclosureSEC source: 0000899243-19-008760 · doc4.xml · nonDerivative · entry 2 Siu Christine · CIK 0001743029 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,952 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 30, 2018 Filed Mar 21, 2019 20:50 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | GrantCommon Stock | 1,081 | $12.01 | $12,982.81 |
DisclosureSEC source: 0000899243-19-008760 · doc4.xml · nonDerivative · entry 1 Siu Christine · CIK 0001743029 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,081 F1 · kind: Shares acquired pursuant to the Issuer's 2018 Employee Stock Purchase Plan. Read SEC document |
| November 05, 2018 Filed Nov 7, 2018 19:11 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | GrantStock Option (right to buy) · Derivative | 55,000 | $0.00 Strike: $13.20 | $0.00 |
DisclosureSEC source: 0000899243-18-028486 · doc4.xml · derivative · entry 1 Siu Christine · CIK 0001743029 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2028-11-05 F1 · derivative.exercise_date: The Reporting Person is a participant in the Issuer's 2018 Stock Option and Incentive Plan and received 55,000 stock options (the "Grant") on November 5, 2018. The shares subject to the Grant shall vest as follows: one quarter of the shares shall vest on November 5, 2019 and the remaining unvested shares shall vest ratably over the following 36 months, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.